Loading...
Market
How will public health guidelines change for APOE e4 carriers and sleep aids by end of 2025?
2
Resolution / Starting Odds
Guidelines recommend against use • 25%
Guidelines remain unchanged • 25%
Guidelines suggest caution • 25%
Guidelines promote alternative treatments • 25%
Updates from public health organizations such as WHO or CDC
Story
Study Links Common Sleep Medications to Impaired Brain Cleansing and 60% Increased Alzheimer's Risk for APOE e4 Gene Carriers
Jan 9, 2025, 07:05 AM
Recent studies indicate that sleep plays a crucial role in the brain's ability to remove waste, functioning as a 'rinse cycle' that flushes out toxins accumulated during wakefulness. However, research conducted on mice has found that certain common sleeping medications may hinder this cleansing process, potentially increasing the risk of Alzheimer's disease. Specifically, some of the most widely used sleep aids in Spain have been linked to brain damage and a higher likelihood of Alzheimer's. Additionally, a study highlighted that women taking Hormone Replacement Therapy (HRT) and possessing the APOE e4 gene may face a 60% increased risk of Alzheimer's-related markers. The findings underscore the importance of understanding the implications of sleep aids and hormone treatments on brain health.
View original story
Similar markets
Roche • 25%
Other • 25%
Pfizer • 25%
Sanofi • 25%
2 • 25%
3 or more • 25%
0 • 25%
1 • 25%
Other • 25%
Denmark • 25%
Spain • 25%
United States • 25%
No • 50%
Yes • 50%
70% to 80% • 25%
More than 80% • 25%
Less than 60% • 25%
60% to 70% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 100,000 • 25%
More than 300,000 • 25%
200,001 to 300,000 • 25%
100,000 to 200,000 • 25%